{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lu-177&page=2", "query": { "intervention": "Lu-177", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lu-177&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T12:24:20.188Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05278208", "title": "Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Glioma", "Meningioma", "Embryonal Tumor", "Medulloblastoma", "Anaplastic Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "LUTATHERA® (Lutetium Lu 177 dotatate)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "4 Years to 39 Years" }, "enrollment_count": 65, "start_date": "2022-11-21", "completion_date": "2033-11", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 4, "location_summary": "Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05278208" }, { "nct_id": "NCT05870579", "title": "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "[68Ga]Ga-NeoB", "type": "DRUG" }, { "name": "[177Lu]Lu-NeoB", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Goserelin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 28, "start_date": "2023-11-13", "completion_date": "2032-05-27", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05870579" }, { "nct_id": "NCT04082520", "title": "Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Grade 1 Meningioma", "Grade 2 Meningioma", "Grade 3 Meningioma", "Recurrent Meningioma", "Unresectable Meningioma" ], "interventions": [ { "name": "Gallium Ga 68-DOTATATE", "type": "RADIATION" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-04-14", "completion_date": "2032-03-04", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04082520" }, { "nct_id": "NCT06955169", "title": "Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intracranial Meningioma" ], "interventions": [ { "name": "[177Lu]Lu-DOTATATE", "type": "DRUG" }, { "name": "Standard of Care treatments", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "RTOG Foundation, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2025-08-24", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 16, "location_summary": "Irvine, California • La Jolla, California • New Haven, Connecticut + 12 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06955169" }, { "nct_id": "NCT03206060", "title": "Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pheochromocytoma", "Paraganglioma", "Neuroendocrine Tumors", "Neuroendocrine Neoplasms" ], "interventions": [ { "name": "Lu-177-DOTATATE", "type": "DRUG" }, { "name": "Ga-68-DOTATATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 130, "start_date": "2017-10-10", "completion_date": "2033-01-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03206060" }, { "nct_id": "NCT07169825", "title": "Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Lu-177 PSMA" ], "interventions": [ { "name": "Lu-177", "type": "DRUG" }, { "name": "SPECT", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 25, "start_date": "2026-03-30", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07169825" }, { "nct_id": "NCT04276597", "title": "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Neuroendocrine Neoplasm", "Pheochromocytoma", "Paraganglioma", "Thymus Carcinoid", "Unknown Primary Tumors", "Neuroendocrine Tumors", "Neuroendocrine Skin Carcinoma", "Neuroendocrine Breast Tumor", "Neuroendocrine Carcinoma Metastatic", "Neuroendocrine Neoplasm of Ovary" ], "interventions": [ { "name": "177Lu-DOTATOC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Excel Diagnostics and Nuclear Oncology Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-03-04", "completion_date": "2021-07-15", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04276597" }, { "nct_id": "NCT02658968", "title": "Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed, Diffuse Large B-cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Betalutin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nordic Nanovector", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2017-03-02", "completion_date": "2021-07-10", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 3, "location_summary": "San Diego, California • San Francisco, California • Miami, Florida", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02658968" }, { "nct_id": "NCT06122610", "title": "Using Novel Imaging to More Safely Treat Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroendocrine Tumors", "Somatostatin Receptor-positive Neuroendocrine Tumor" ], "interventions": [ { "name": "Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)", "type": "DEVICE" }, { "name": "Photon Emission Tomography / CT (PET/CT)", "type": "DEVICE" }, { "name": "64Cu-Dotatate", "type": "DRUG" }, { "name": "177Lu-Dotatate", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2025-03-07", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06122610" }, { "nct_id": "NCT06052306", "title": "A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "BAY3546828", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 232, "start_date": "2023-09-20", "completion_date": "2031-08-10", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-22T12:24:20.188Z", "location_count": 5, "location_summary": "Duarte, California • Minneapolis, Minnesota • Omaha, Nebraska + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052306" } ] }